Investors

  • TSX.V: DXD
  • OTCQB: TDSGF FSE: 3D0

CONTACT

Investor Relations
E investors@3dsignatures.com
T 416-673-8487

Stock Information (as of March 27, 2018)

Issued and Outstanding Shares 63,925,905
Warrants 15,616,698
Options 3,786,552
Fully Diluted Shares 83,329,155
Board and
Management Ownership
25%

INVESTMENT HIGHLIGHTS

1. BREAKTHROUGH TECHNOLOGY

Proprietary TeloView™ software algorithms could represent a major medical advancement in patient diagnosis, treatment and the development of companion diagnostics in precision medicine.

Structural biomarker based on 3D telomere organization.

2. VALIDATION IN 2018

Completion of HL clinical trial and validation of Telo-HL™ test will introduce 1st in class 3D telomere biomarker to diagnostic market.

External validation is expanding through PoC studies in PC, LC, MM.

3. TELOVIEW™ IS A PLATFORM

20 cancers + Alzheimer’s disease have all tested positively in 25+ clinical studies.

Platform is agnostic to the underlying mutations and acts as a universal marker of genomic instability.

 

4. EXPERT TEAM

Accomplished leadership and scientific team with ability to develop and commercialize platform and secure strategic partners.

World-class Scientific and Business advisors supporting 3DS.

5. SCALABLE BUSINESS MODEL

Tests can be commercialized as LDT’s in NA and CE in EU.

Option to partner with industry majors through licensing agreements. Pharma services and CDx opportunities in discussion.

 

6. FISCAL MANAGEMENT

Driving growth through strategic allocation of capital.

Controlling expenses through streamlined operations and tight fiscal management.

 

 

FINANCIALS

LICENSING

3D Signatures is actively seeking potential licensing opportunities. To discuss a partnering or collaboration opportunity, please submit your query to info@3dsignatures.com.